by CN Bio. | Mar 1, 2021 | Press releases
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s...
by CN Bio. | Jan 11, 2021 | Press releases
FDA publication demonstrates advantages of PhysioMimix™ in drug safety and metabolism applications, over standard techniques Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator Characterizing the...
by CN Bio. | Dec 15, 2020 | Press releases
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection CN Bio, a leading cell culture company, that has developed single and multi-organ...
by CN Bio. | Oct 27, 2020 | Press releases
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
by CN Bio | Aug 5, 2020 | Press releases
Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
by CN Bio. | Mar 2, 2020 | Press releases
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by existing investor CN Innovations Headquarters relocated to larger premises in Cambridge Science Park, a leading UK life sciences...
